Curr Opin Pulm Med 2017 09;23(5):418-425
aCenter for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg bMember of the German Center for Lung Research cDepartment of Internal Medicine V, Comprehensive Pneumology Center, Asklepios Fachkliniken, University of Munich, Munich, Bavaria, Germany.
Purpose Of Review: Therapeutic advances in the management of idiopathic pulmonary fibrosis (IPF) has led to improved outcomes with the use of the antifibrotic agents pirfenidone and nintedanib, with a number of randomized studies demonstrating benefits in slowing disease progression in IPF. However, treatment of other fibrosing interstitial lung diseases (ILD) remains challenging.
Recent Findings: Observational and uncontrolled studies investigating pirfenidone and nintedanib in non-IPF ILDs suggest potential benefits, although the data is weak. Read More